This platform can help identify early symptoms of diseases like atherosclerosis, venous thrombosis, cardiovascular diseases, ...

Singapore-HUJ Alliance for Research and Enterprise, Singapore HUJ Alliance Research Enterprise (SHARE) 1 CREATE Way, #03-09 Innovation Wing, Singapore 138602, Singapore ...

Membrane trafficking is the process by which proteins and other macromolecules are distributed throughout the cell, and released to or internalised from the extracellular space. Membrane ...

The drug has demonstrated an unprecedented ability to lower levels of lipoprotein(a), or Lp(a), a genetically inherited risk factor for cardiovascular disease. In a mid-stage clinical trial, patients ...

Pistachios are packed with vital nutrients like potassium, fiber, vitamin C, and antioxidants, making them a healthy snacking choice. A serving size is 1 ounce, which is about 49 kernels. While ...

Credit: Shutterstock / Dmytro Zinkevych. Eli Lilly has reported promising Phase II results for lepodisiran, its experimental therapy aimed at reducing lipoprotein(a) [Lp(a)], a genetically inherited ...

CHICAGO -- Novel small interfering RNA (siRNA) agent lepodisiran drastically cut levels of lipoprotein(a), or Lp(a), in the phase II ALPACA trial. The 400-mg dose cut Lp(a) by 93.9 percentage ...

Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting ...

The ALPACA trial showed that among patients with elevated lipoprotein(a), lepodisiran reduces mean serum concentrations of lipoprotein(a) from 60 to 180 days after administration. Participants were ...

Lepodisiran greatly lowered lipoprotein(a) at 6 months and 1 year compared with placebo. A cardiovascular outcomes trial of lepodisiran is underway. Perspective from Robert S. Rosenson, ...